Altoida provides digital health solutions. The company utilizes active digital biomarkers and technology in artificial intelligence (AI) and augmented reality (AR). The company was founded in 2016 and is based in Washington, DC.
ESPs containing Altoida
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The digital therapeutics — neurodegenerative market offers innovative solutions for the treatment and management of neurodegenerative diseases such as alzheimer's, parkinson's, and multiple sclerosis (MS) through technology-based interventions. These interventions can include cognitive training, physical therapy, and other forms of behavioral intervention delivered through digital platforms, mobil…
Altoida's Products & Differentiators
Altoida's Precision Neurology Device
Smartphone/tablet-based app to measure and monitor neurocognitive function and predict neurological disease onset.
Research containing Altoida
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Altoida in 5 CB Insights research briefs, most recently on Aug 9, 2023.
Expert Collections containing Altoida
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Altoida is included in 6 Expert Collections, including AR/VR.
This collection includes companies creating hardware and/or software for augmented reality, virtual reality, and mixed reality applications.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Digital Health 150
The winners of the third annual CB Insights Digital Health 150.
Precision Medicine Tech Market Map
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Altoida has filed 2 patents.
Audio engineering, Augmented reality, Virtual reality, Mobile computers, Cognition
Audio engineering, Augmented reality, Virtual reality, Mobile computers, Cognition
Latest Altoida News
Oct 25, 2023
Background 25.10.2023 Recent studies have demonstrated the effectiveness of Kleinico’s mental health diagnostic tool and Altoida’s AR-based digital cognitive and functional assessment, representing a new clinical step for the companies, as well as a hope for millions of people affected by these conditions. A newly launched global study will rely on Aktiia’s cuffless blood pressure monitoring solution. The Klenico system is a novel diagnostic tool aiming to capture the complexity and diversity of mental disorders. It uses a comprehensive online survey covering various psychological functioning dimensions, such as emotions, cognitions, behaviours, and interpersonal relationships. The Klenico system generates a graphical representation of the patient’s profile, facilitating diagnosis and treatment planning. To evaluate the validity and reliability of the Klenico system, Klenico conducted a large-scale study with 600 patients from outpatient and inpatient psychosomatic care and compared it with other standard diagnostic instruments, such as the Patient Health Questionnaire (PHQ), the Beck Depression Inventory-II (BDI-II), and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The analyses show strong correlations between the majority of the disorders depicted by Klenico and the comparison instruments, proving the study’s construct validity. In addition, the Klenico disorders align with the Structured Clinical Interview for DSM-IV (SKID), the gold standard in diagnostics. These promising results illustrate that Klenico, as a valid and digital tool, can provide targeted and efficient support to professionals in the diagnosis of mental illnesses and thus contribute to evidence-based diagnoses and therapies. Altoida AR-based digital cognitive and functional assessment In its latest study conducted in Barcelona, Altoida found that its AR-based digital cognitive and functional assessment - in 188 MCI and healthy volunteers - provides a Digital Neuro-Signature™ (DNS-MCI) score, which correlates with standard neuropsychological tests such as the Mini-Mental State Examination (MMSE), Free and Cued Selective Reminding Test (FCSRT) and the Trail Making Test (TMT). The Swiss startup is developing digital neurological disease biomarkers using augmented reality (AR) and machine learning (ML). The Altoida digital cognitive assessment is a research device based on AR and ML that simulates conducting activities of daily living, providing an objective measure of cognitive and functional abilities in approximately 10 minutes, compared to pen-and-paper neuropsychological tests that take approximately 60-90 minutes. Aktiia participates in landmark study Pionieering cuffless blood pressure monitoring, Aktiia has been selected to participate in the Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP) study, a large prospective cohort study in the Principality of Liechtenstein composed of more than 2000 participants followed for > 1 decade to determine the genetic and phenotypic factors for blood pressure and cardiovascular diseases. Aktiia's unique 24/7 Blood Pressure monitoring technology will play a key role in its ongoing research. The study aims to pave the way for more personalized, proactive, and patient-driven healthcare. This collaboration aims to unlock the links between longitudinal blood pressure patterns and genetic, biomarkers, imaging, and healthcare data, paving the way for groundbreaking discoveries in the field. Further participants include Professors David Conen MD MPH at McMaster University and Lorenz Risch MD MPH at the Private University of Liechtenstein and the Dr. Risch Laboratory. (RAN)
Altoida Frequently Asked Questions (FAQ)
When was Altoida founded?
Altoida was founded in 2016.
Where is Altoida's headquarters?
Altoida's headquarters is located at 80 M Street South East, Washington.
What is Altoida's latest funding round?
Altoida's latest funding round is Series A - III.
How much did Altoida raise?
Altoida raised a total of $21.53M.
Who are the investors of Altoida?
Investors of Altoida include VI Partners, Fyrfly Venture Partners, Alpana Ventures, Hikma Ventures, b2venture and 12 more.
Who are Altoida's competitors?
Competitors of Altoida include ViewMind, Perceiv AI, BrainCheck, Neurotrack, Cumulus Neuroscience and 7 more.
What products does Altoida offer?
Altoida's products include Altoida's Precision Neurology Device and 1 more.
Who are Altoida's customers?
Customers of Altoida include BioCare.
Compare Altoida to Competitors
Best Covered uses continuous data analysis and technology to empower health management, helping middle-aged and elderly groups to effectively identify, intervene, and delay risks so that people can live healthier and happier lives. The company was founded in 2016 and is based in Shanghai, China.
BrainCheck focuses on cognitive health, operating in the healthcare technology sector. The company offers a digital platform that provides cognitive assessments, clinical decision support, and cognitive care planning. These services are designed to help healthcare providers identify and manage dementia and cognitive impairment in their patients. BrainCheck was founded in 2014 and is based in Austin, Texas.
Neurotrack offers a digital medicine solution for Alzheimer's disease. It develops cognitive screening tools to help healthcare providers and individuals assess and monitor diseases. It streamlines workflows, identifies impairment early, and provides new pharmaceutical treatment options. The company was founded in 2012 and is based in Redwood City, California.
Darmiyan develops neuroscience-powered artificial intelligence and brain imaging software. It produces maps that detect Alzheimer's disease. The company technology provides a platform for presymptomatic diagnosis of neurodegenerative disorders with specific quantification and localization of microscopic abnormality in the brain. It was founded in 2016 and is based in Berkeley, California.
Cumulus Neuroscience develops a home usable headset that can objectively probe neuronal integrity, network connectivity, and the strategies the brain uses to compensate for neuronal damage. The platform provides secure cloud-based data storage and a machine learning architecture to safely analyze composite behavioral, physiological, and functional data. It was founded in 2015 and is based in Belfast, United Kingdom.
Neuro-Bio is a privately-owned biotech company with a therapeutic focus on neurodegenerative diseases. The company's main services include the discovery and development of drugs to treat Alzheimer's disease, and the development of a biomarker as a companion diagnostic. Neuro-Bio primarily sells to the healthcare and pharmaceutical industries. It was founded in 2013 and is based in Oxfordshire, England.